Chugai Pharma Taiwan Ltd (台灣中外製藥) on Friday was honored at the prestigious Asia Responsible Enterprise Awards (AREA), receiving accolades in the Green Leadership and Social Empowerment categories.
It was the fourth consecutive year the company has received international recognition at AREA, underscoring its long-term commitment and tangible achievements in environmental sustainability and social responsibility.
This year’s AREA ceremony was held in Bangkok, Thailand, and organized by the non-governmental organization Enterprise Asia. The awards attracted more than 350 entries from 19 countries across Asia, with only 81 projects ultimately selected — an acceptance rate of just 23 percent.
Photo courtesy of Chugai Pharma Taiwan
Chugai Pharma Taiwan’s repeated success highlights its consistent dedication to excellence in environmental, social and governance (ESG) initiatives.
Continuing to expand its ESG impact this year, Chugai Pharma Taiwan partnered with Taiwanese sustainable brand Blueseeds to adopt and support contract farming of herb fields. The Chugai team traveled to Taitung to attend the adoption ceremony, engaged in meaningful dialogue with local contract farmers and planted lavender seedlings by hand — a symbolic gesture of the company’s promise to protect the environment.
In addition, Chugai Pharma Taiwan integrated an essential oil DIY event into its patient support program, empowering people to create their own essential oils to ease stress, and promote physical and mental well-being.
The essential oils, derived from naturally cultivated herbs, were also packaged into gift sets and shared with employees and business partners, promoting a healthy lifestyle and eco-friendly values. The initiative not only supports sustainable agriculture, but also creates diversified employment opportunities for visually impaired perfumers and small-scale local farmers.
Receiving AREA honors for four consecutive years affirms Chugai Pharma Taiwan’s unwavering commitment to ESG values. The company reiterated its mission to address unmet medical needs through innovative medicines, improving access to treatment, and enhancing public health and well-being.
“Our commitment has always been to improve patients’ quality of life and help brighten their lives,” Chugai Pharma Taiwan said. “We will continue to strengthen our ESG strategy and leverage our corporate influence to create lasting, positive change — moving together toward a more sustainable future.”
TECH CORRIDOR: The new Phase II site is expected to work with other facilities in the region and nation as TSMC looks to shape the future with its manufacturing Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) would build three additional advanced packaging facilities in Phase II of the Chiayi Science Park (嘉義科學園區), National Science and Technology Council (NSTC) Minister Wu Cheng-wen (吳誠文) said yesterday. Speaking at the groundbreaking ceremony for the Phase II, Wu said the roughly 90-hectare site would be developed into an advanced packaging industry cluster led by TSMC. Two advanced packaging facilities at Phase I began mass production last month. Wu said that the Phase II development of the Chiayi Science Park would strengthen the resilience of the regional economy and help transform Chiayi County into a global production
MOMENTUM: Second-quarter revenue reached NT$1.27 trillion as the June turnover surged, while TSMC’s 2nm process spending and US expansion remain focus points Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported its highest quarterly sales amid strong global demand for artificial intelligence (AI) applications. The world’s largest contract chipmaker posted NT$1.27 trillion (US$39.5 billion) in consolidated revenue for the second quarter of this year, up 36 percent year-on-year and nearly 12 percent from a quarter earlier. The quarterly figure was bolstered by a very strong performance last month, when TSMC’s revenue was up 67.9 percent from a year earlier and rose 6.2 percent from a month earlier to NT$442.68 billion, a new monthly high, TSMC said in a statement. At its earnings conference in April, TSMC
United Microelectronics Corp (UMC, 聯電), the second largest contract chipmaker in Taiwan, said yesterday that it has started mass production of silicon photonics wafers at its 12-inch wafer fab in Singapore. The first batch of silicon photonics wafers in commercial production was achieved in collaboration with Singapore-based silicon photonics fabless firm Silith Technology Pte Ltd, which took delivery of the batch of products, UMC said in a statement. UMC said the cooperation integrated Silith’s photonics design expertise with UMC’s 12-inch wafer production capacity and process capabilities to support high-volume production of the Singaporean partner’s 1.6 terabits per second (1.6T) silicon photonics platform. The
ASML Holding NV plans to raise prices for its chipmaking equipment, setting up a potential clash with its biggest customer, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), The Information reported on Wednesday, citing people familiar with the matter. TSMC is already pushing back against the Dutch toolmaker’s plans, The Information reported. TSMC declined to comment. A representative for ASML pointed to comments by its chief financial officer, Roger Dassen, during its earnings call on Wednesday about pricing, but declined to comment further. ASML makes the cutting-edge extreme ultraviolet (EUV) lithography machines that are necessary for chipmakers to manufacture advanced semiconductors and is experiencing a surge
RSS